Compare Eni SpA (E) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Novo Nordisk A/S — how do they compare? Eni SpA trades at $56.08 (market cap $79.81B), while Novo Nordisk A/S trades at $38.47 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.1× Eni SpA's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Novo Nordisk A/S for 116 Days on average.
| E | NVO | |
|---|---|---|
Market Cap | $79.81B | $165.31B |
Volume | 365,912 | 11,432,838 |
Sector | Energy | Health |
52-Week High | $57.61 | $63.98 |
52-Week Low | $34.03 | $35.29 |
Typical Hold Time | 53 Days | 116 Days |
Enterprise Value | $104.34B | $179.56B |
Dividend Yield | 4.39% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $56.02, up 3.82% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows attractive valuation with a P/E of 12.87 and P/S of 0.85. Recent earnings have been mixed, with Q4 2025 beating estimates but Q1 and Q2 2026 missing. Revenue has declined from $132.5B in 2022 to $82.2B in 2025, though net income margin improved to 5.97% in 2026. Positive news includes expansion in Venezuela, Indonesia, and humanoid robotics partnerships.
Outlook is cautiously optimistic given low valuations and strategic initiatives, but risks include volatile energy prices and execution challenges. Analyst consensus is mixed with 34.6% buy ratings. Earnings growth and operational efficiency are key catalysts for upside, while geopolitical and macroeconomic factors pose headwinds.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
